August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
1 citations
,
March 1997 in “Journal of Chromatography B: Biomedical Sciences and Applications” Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.
April 2018 in “Journal of Investigative Dermatology” CREB, a protein that can promote cancer traits, is controlled by β-catenin in skin cancer cells.
3 citations
,
April 2014 in “Journal of Dietary Supplements” CARI ONE helps start hair growth and makes hair follicles bigger and more numerous.
The treatment was ineffective in humans.
April 2026 in “Therapeutic Advances in Drug Safety” Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.
Men with early-onset hair loss are less responsive to bromocriptine's heart and metabolism benefits.
A new mutation in the CYP11B1 gene was found in a woman with mild hyperandrogenemia, a rare cause of non-classic congenital adrenal hyperplasia.
55 citations
,
December 1983 in “Acta Neurologica Scandinavica” Carbamazepine, valproate, and clonazepam can cause mild to serious side effects during long-term epilepsy treatment.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
15 citations
,
April 2011 in “The journal of investigative dermatology/Journal of investigative dermatology” A3B5 can reduce skin pigmentation and slow melanoma growth.
6 citations
,
February 2023 in “Advances in Therapy” Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
August 2025 in “ACS Omega” New compounds show promise as nonsteroidal treatments for hair loss.
May 2010 in “Europe PMC (PubMed Central)” Near-infrared probes can safely and effectively image cysteine protease activity for disease diagnosis.
44 citations
,
October 2016 in “Epilepsia” 2-DG reduces seizures by enhancing brain inhibition through specific receptor activation.
December 2025 in “Scientific Reports” Cedrol may help reduce liver fat and fat cell growth caused by corticosteroids.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
September 2019 in “Journal of Investigative Dermatology” Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
17 citations
,
June 1996 in “The Journal of Steroid Biochemistry and Molecular Biology” FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
2-Hydroxy-1,4-naphthoquinone is a strong 5α-reductase inhibitor.
6 citations
,
January 2013 in “Chemical & pharmaceutical bulletin/Chemical and pharmaceutical bulletin” A new compound shows promise as a topical treatment for hair loss.
October 2024 in “BMJ Case Reports” Baricitinib effectively treats both rheumatoid arthritis and alopecia areata.
20 citations
,
January 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is the most effective treatment for alopecia areata.
11 citations
,
September 2021 in “Journal of molecular endocrinology” ERβ has potential in treating prostate cancer and neurodegenerative diseases, but human studies are needed before clinical use.
March 2010 in “Anti-inflammatory & anti-allergy agents in medicinal chemistry” Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.
August 2016 in “Journal of Investigative Dermatology” The endocannabinoid system affects oil production and inflammation in skin cells.
28 citations
,
December 2001 in “European Journal of Pharmacology” M50054 may help treat hepatitis and hair loss from chemotherapy.
17 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.